Understand the source comparison
Top Selling Peptides August 2026: Research Category Comparison
The following table summarizes the primary peptides driving August 2026 demand across metabolic, cognitive, and tissue-repair research categories. Ranked by procurement volume and characterized by mechanism, primary research application, and typical dosing ran
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table summarizes the primary peptides driving August 2026 demand across metabolic, cognitive, and tissue-repair research categories. Ranked by procurement volume and characterized by mechanism, primary research application, and typical dosing range used in current institutional protocols.
- Tirzepatide
- Dual GIP/GLP-1 receptor agonist
- Obesity, NAFLD, cardiometabolic syndrome
- 5–15mg weekly subcutaneous
- Highest absolute volume. Driven by hepatic fat reduction studies beyond weight loss
- Semaglutide
- GLP-1 receptor agonist
- Metabolic disease, neuroprotection in AD models
- 0.5–2.4mg weekly subcutaneous
- Steady demand. Expanding into Alzheimer's disease research
- BPC-157
- Angiogenesis promotion, collagen synthesis
- Tendon/ligament repair, GI healing
- 200–500mcg daily subcutaneous
- 3rd highest volume. Surgical recovery and tendinopathy models
- Dihexa
- HGF mimetic, BDNF/NGF pathway activation
- Cognitive decline, Alzheimer's disease
- 1–5mg/kg oral or subcutaneous
- Fastest growth. 340% increase year-over-year
- TB-500
- Thymosin beta-4 analog, actin upregulation
- Vascular injury, tissue regeneration
- 2–10mg twice weekly subcutaneous
- 5th position. Often compared head-to-head with BPC-157
- Cerebrolysin
- Porcine neurotrophic factor mixture
- Stroke recovery, traumatic brain injury
- 10–30ml IV infusion
- 6th rank. Replication of European stroke recovery trials
- Thymalin
- Thymic peptide bioregulator
- Immune senescence, T-cell restoration
- 5–10mg daily subcutaneous for 10-day cycles
- 7th position. Gerontology labs testing healthspan extension
- Retatrutide
- Triple GLP-1/GIP/glucagon agonist
- Obesity, NASH, extreme weight loss models
- 8–12mg weekly subcutaneous
- New entry. Triple-receptor activity driving comparative studies